Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak’s Takeover Bid Valued Up To $7.75/Share
Vanda Pharmaceuticals rebuffs unsolicited proposals from Future Pak LLC, citing undervaluation. Offers up to $7.75 per share. Board asserts resilient business with FDA-approved products. Future Pak urged to reconsider terms for fair shareholder value.